| Hans-Günter Meyer-Thompson | Buprenorphin
New…and improved? The latest studies on injectable buprenorphine for opioid use disorder
New…and improved? The latest studies on injectable buprenorphine for opioid use disorder
Suboxone is a first-line treatment for opioid use disorder. The need to take it daily, however, increases the risk that someone will miss a dose. Suboxone misuse and diversion also remain prominent concerns. Novel, FDA-approved injection formulations of buprenorphine, the active ingredient in Suboxone, were designed to address these potential drawbacks. Two recent studies show that injection buprenorphine outperforms a placebo injection and does as well as daily sublingual Suboxone. (Recovery Bulletin, USA, Dezember 2019)
https://www.recoveryanswers.org/research-post/monthly-injectable-buprenorphine/